In the current competitive biotherapeutic market, predominantly driven by antibody molecules, bispecific antibodies represent a key component of the next generation of antibody therapy. Immunoglobulin G (IgG), the most common type of antibody found in blood circulation, are monospecific and recognize only a single antigen, with the exception of IgG4. In contrast, bispecific antibodies are designed to recognize and bind to two different targets.
This is useful as a therapeutic as they can be designed to redirect, for instance, immune cells such as T cells, to selectively engage and eliminate target tumor cells, by allowing effective binding of tumor cell receptors while also recruiting cytotoxic immune cells. In addition, bispecific antibodies can assist in the delivery of therapeutic payloads, such as toxins or drugs, to specific sites in the body.
There are several approaches to producing bispecific antibodies, with the common methods being:
Knobs-in-holes
Ig-scFv fusion
Diabody-Fc fusion
Dual-Variable-Domain-IgG
Biointron has expressed thousands of bispecific antibodies, and we have extensive experience in bispecific antibody production. We take pride in our ability to cater to any client request, offering a wide array of formats in bispecific antibody production.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
